SCHEMBL2654920

SCHEMBL2654920

CCOC(=O)CCCOc1ccc(C=O)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.44
ALDH1A1 P00352 8/20 0.44
HPGD P15428 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP1A2 P05177 2/20 0.44
HSP90AA1 P07900 1/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PDK2 Q15119 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7367306 0.84 FDPS (0.67) FDPSALDH1A1HPGDPOLBMAPT
SCHEMBL17821696 0.84 FDPS (0.58) FDPSALDH1A1HPGDMAPTCYP2C9
SCHEMBL6313264 0.83 FFAR4 (0.49) FDPSALDH1A1HPGDMEN1KMT2A
SCHEMBL24136504 0.83 MEN1 (0.43) HPGDMEN1KMT2AMAPTCYP1A2
SCHEMBL16607418 0.83 MEN1 (0.43) MEN1KMT2APOLBCYP1A2CYP2C19
SCHEMBL15244044 0.83 TNF (0.46) ALDH1A1MEN1KMT2APOLBMAPT
SCHEMBL10291447 0.82 FDPS (0.53) FDPSALDH1A1HPGDMEN1KMT2A
SCHEMBL16607414 0.81 APP (0.56) FDPSALDH1A1HPGDMEN1KMT2A
SCHEMBL1443525 0.80 FDPS (0.54) FDPSALDH1A1HPGDMEN1KMT2A
SCHEMBL2585951 0.80 ALDH1A1 (0.60) FDPSALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585517-A1 USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2005-10-19 EP disclosed
US-20050014810-A1 Use of substituted 2 phenylbenzimidazoles as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-01-20 US disclosed
WO-2004062663-A1 USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014810-A1 Use of substituted 2 phenylbenzimidazoles as medicaments GLP1R, GIPR, GCGR FDPS 3194/4885ALDH1A1 1506/4885HPGD 2861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.